US Preventive Services Task Force Recommendations on Ovarian Cancer Screening

Overview of Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related fatalities among women in the United States, accounting for approximately 14,000 deaths annually.

USPSTF Findings on Screening

In a recent article published in JAMA, the US Preventive Services Task Force (USPSTF) stated that they do not recommend ovarian cancer screening for women who are asymptomatic and not identified as being at high risk. The task force reviewed the risks and benefits of screening in this demographic, specifically excluding women with genetic predispositions to BRCA1 or BRCA2 mutations, who are known to be at higher risk for breast and ovarian cancer.

Outcomes and Risks of Screening

The USPSTF focused on several key outcomes, including ovarian cancer mortality, quality of life, and the psychological impact of screening. It was noted that many women who tested positive did not have ovarian cancer, resulting in false positives. Furthermore, screening methods such as the CA-125 tumor marker and transvaginal ultrasound did not lead to a reduction in mortality from ovarian cancer.

The task force highlighted that false-positive results often led to unnecessary surgical procedures for many women who did not have the disease. However, the psychological effects of such screenings were not addressed in their report.

Evidence from Large Studies

The USPSTF reviewed three significant studies examining the effectiveness of annual ovarian cancer screening in asymptomatic women. None of these studies demonstrated any benefit for women not at high risk. The largest study was a randomized controlled trial in the United Kingdom, which included 202,638 postmenopausal women aged 50-74. Participants were divided into three groups: one receiving CA-125 screening, another undergoing yearly transvaginal ultrasound, and a control group with no screening. After approximately 11 years, results showed no significant difference in ovarian cancer mortality rates among the groups.

Final Recommendations

In summary, the USPSTF advises against ovarian cancer screening for asymptomatic women who are not at high risk, concluding that the potential harms outweigh any possible benefits. This stance aligns with the recommendations from the American College of Obstetrics and Gynecologists and the American Academy of Family Physicians, which also discourage screening for low-risk women.

Reference

Grossman, D., Curry, S., Owens, D., Barry, M., Davidson, K., & Doubeni, C. et al. (2018). Screening for Ovarian Cancer. JAMA, 319(6), 588.